Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + SOX
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
fruquintinib + SOX is a combination neoadjuvant therapy regimen being evaluated for the treatment of locally advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. The regimen consists of fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR-1, 2, and 3, combined with the SOX chemotherapy regimen (S-1 plus oxaliplatin). Fruquintinib, developed by HUTCHMED, inhibits tumor angiogenesis, while SOX provides cytotoxic effects through DNA cross-linking (oxaliplatin) and inhibition of thymidylate synthase (S-1). This specific combination is being investigated in a Phase II clinical trial sponsored by Guangxi Medical University to improve R0 resection rates and long-term survival in patients with stage III disease.
- Other names
- Fruquintinib plus SOXFruquintinib + S-1 + OxaliplatinFruquintinib + Tegafur/Gimeracil/Oteracil + Oxaliplatin
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNADPYD (Dihydropyrimidine dehydrogenase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)OPRT (Orotidine 5'-phosphate decarboxylase)RET (Rearranged during transfection receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on fruquintinib + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + SOX.